Life sciences investment group raises funds to invest in healthcare innovation
European life sciences investment group, LSP has successfully raised €280 million in funding, which will be used to invest in private companies with innovative healthcare products in the field of medical devices, diagnostics and digital health.
The LSP Health Economics Fund 2 (LSP HEF 2) was oversubscribed and exceeded both its target size and its original ‘hard cap’, making it the largest fund in Europe dedicated to medical technology.
“The success of this fundraising is a strong validation of our strategy – investing in medical innovation to benefit both patients, and investors. As with the first LSP Health Economics Fund, we plan to invest in companies with products that can improve quality of care and lower healthcare spending,” commented Dr Rudy Dekeyser, managing partner of LSP HEF 2. “Our portfolio companies not only contribute to the sustainability of today’s healthcare systems, they also tend to be highly successful in the market, leading to fast adoption and making them attractive acquisition targets. Success stories like Neuravi and Rotation Medical from the first LSP Health Economics Fund are great examples of how our strategy can combine the best patient care with superior returns to our investors. We look forward to continuing this investment strategy with LSP HEF 2.”
“With this new and sizable fund, we have now firmly established our health economics and medical technology strategy,” added Dr René Kuijten, managing partner of LSP. “Together with our other fund strategies, LSP 1-5 investing mainly in drug development and LSP Public investing in public healthcare companies, we now cover the entire life sciences landscape as one of Europe’s largest investors in the sector.”
The investor base in LSP HEF 2 includes the European Investment Fund (EIF), health insurance companies, institutional investors, asset managers and family offices. The fund will be used to invest in around 15 private companies across the areas of medical devices, diagnostics and digital health. The products of these companies should be on the market or very close to market introduction and have the potential to lower costs for healthcare systems while also providing improved quality of care to patients.